BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/12/2024 12:23:34 PM | Browse: 246 | Download: 1012
 |
Received |
|
2024-07-22 00:26 |
|
Peer-Review Started |
|
2024-07-22 00:26 |
|
First Decision by Editorial Office Director |
|
2024-08-17 19:16 |
|
Return for Revision |
|
2024-08-17 19:16 |
|
Revised |
|
2024-08-31 10:45 |
|
Publication Fee Transferred |
|
2024-09-25 14:34 |
|
Second Decision by Editor |
|
2024-09-19 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-19 08:17 |
|
Articles in Press |
|
2024-09-19 08:17 |
|
Edit the Manuscript by Language Editor |
|
2024-10-11 10:52 |
|
Typeset the Manuscript |
|
2024-10-16 03:17 |
|
Publish the Manuscript Online |
|
2024-11-12 12:23 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wagner Eduardo Cruz-Diaz, Victor Paitan, Jersinho Medina, Raymundo Flores, Juan Haro-Varas, Raul Mantilla and Victor Castro-Oliden |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wagner Eduardo Cruz-Diaz, MD, Staff Physician, Department of Oncology, Instituto Nacional de Enfermedades Neoplasicas, Avenue Angamos Este 2520, Surquillo, Lima 15038, Peru. wagner.cruz@upch.pe |
| Key Words |
Well-differentiated; Gastroenteropancreatic neuroendocrine tumors; Capecitabine; Temozolomide; Retrospective study; Treatment; Chemotherapy |
| Core Tip |
In this study, patients diagnosed with advanced gastroenteropancreatic neuroendocrine tumors who were treated with the temozolomide and capecitabine regimen exhibited a median overall survival of 49 months, with 42% surviving at 60 months. The regimen was well-tolerated, and most patients experienced stable disease. These findings suggest that this treatment could be viable in settings where standard therapies are unavailable or inaccessible, though further prospective studies are needed for confirmation. |
| Publish Date |
2024-11-12 12:23 |
| Citation |
Cruz-Diaz WE, Paitan V, Medina J, Flores R, Haro-Varas J, Mantilla R, Castro-Oliden V. Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center. World J Gastrointest Oncol 2024; 16(12): 4675-4684
|
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i12/4675.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i12.4675 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
